The patent application WO2018117152 relates to delgocitinib, a Janus kinase (JAK) inhibitor. The application was filed by AnGes MG Inc. and concerns methods for treating immune and inflammatory diseases.
What is delgocitinib used for?
Delgocitinib is being investigated for the treatment of immune and inflammatory diseases. The patent application specifically mentions its potential use in treating conditions such as rheumatoid arthritis, systemic lupus erythematosus, psoriasis, atopic dermatitis, and inflammatory bowel disease [1].
What does patent WO2018117152 claim about delgocitinib?
Patent application WO2018117152 claims methods for treating diseases using delgocitinib. It outlines specific dosages and treatment regimens for administering the drug to patients suffering from immune and inflammatory conditions [1]. The application details the preparation and use of delgocitinib for therapeutic purposes.
When does the patent for delgocitinib expire?
Information regarding the specific expiry date of patent WO2018117152 is not directly available in the provided context. Patent applications undergo examination and can lead to granted patents with defined terms. To determine the exact patent expiry and any related exclusivities for delgocitinib, one would need to consult patent databases and regulatory filings. DrugPatentWatch.com can provide detailed information on patent status and expiry dates for pharmaceuticals [2].
Who is developing delgocitinib?
AnGes MG Inc. is listed as the applicant for the patent application WO2018117152 concerning delgocitinib [1]. Subsequent development and commercialization efforts may involve collaborations or licensing agreements with other pharmaceutical companies.
What are the potential side effects of delgocitinib?
While the patent application focuses on the therapeutic methods, clinical trials and post-marketing surveillance would detail the known side effects of delgocitinib. As with other JAK inhibitors, potential side effects can include increased risk of infections, changes in blood cell counts, and gastrointestinal issues. Specific patient concerns and reported adverse events are typically documented in prescribing information and medical literature.
How does delgocitinib work?
Delgocitinib is a selective inhibitor of Janus kinases (JAKs). JAKs are intracellular enzymes involved in signaling pathways that regulate immune responses and inflammation. By inhibiting specific JAK enzymes, delgocitinib can modulate the immune system and reduce inflammatory processes in various diseases [1].
Are there other JAK inhibitors available?
Yes, several other JAK inhibitors are approved for various indications. These include drugs like tofacitinib, baricitinib, and upadacitinib, which target JAK pathways for the treatment of conditions such as rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis. Delgocitinib's specific JAK selectivity and therapeutic profile may differentiate it from other agents in this class.
Can biosimilars be developed for delgocitinib?
The development of biosimilars for biologic drugs is a complex process. For small molecule drugs like delgocitinib, the equivalent concept is generic versions. Generic versions can be approved and marketed after the expiration of relevant patents and any other market exclusivities. The patent status and exclusivities, as tracked by resources like DrugPatentWatch.com, are critical for determining when generic competition might occur [2].
What is the regulatory status of delgocitinib?
The regulatory status of delgocitinib depends on the jurisdictions where it is being developed and reviewed. Information on its approval status for specific indications would be available through regulatory agencies like the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and may also be found in company press releases and clinical trial registries.
Sources:
[1] https://patents.google.com/patent/WO2018117152A1/
[2] https://www.drugpatentwatch.com/